Relafin 100 mg (Tablet)

Indications

• Obsessive-Compulsive Disorder
• Depressive illness
• Panic Disorder
• Eating Disorders
• Chronic Tension Headache

Pharmacology

• Inhibition of CNS neuronal uptake of serotonin
• Enhancement of actions of serotonin on 5HT1A autoreceptors
• Virtually no affinity for certain receptors

Dosage & Administration

• Recommended starting dose for adults: 50 mg
• Titration within a dose range of 100 to 300 mg/day for adult patients
• Recommended starting dose for pediatric populations (ages 8-17 years): 25 mg
• Titration within a dose range of 50 to 200 mg/day for pediatric patients
• Dose adjustment in adolescents may be indicated to achieve therapeutic benefit
• Dose modification for elderly or hepatically impaired patients

Interaction

• Inhibition of cytochrome P450 isoenzymes
• Elevated levels and symptoms of toxicity with coadministration of carbamazepine
• Rare postmarketing reports of weakness, hyperreflexia, and incoordination with sumatriptan
• Increased tacrine C max and AUC with coadministration of tacrine
• Significantly increased plasma TCA levels with coadministration of tricyclic antidepressants (TCAs)
• Severe vomiting with coadministration of tryptophan
• Bradycardia with coadministration of diltiazem
• Dose reduction and cautious titration when coadministered with propranolol or metoprolol

Contraindications

• Coadministration of tizanidine, thioridazine, alosetron, pimozide
• Serotonin Syndrome and MAOIs
• Do not use within 14 days of stopping an MAOI intended to treat psychiatric disorders
• Do not start in a patient being treated with linezolid or intravenous methylene blue

Side Effects

• Nausea
• Somnolence
• Insomnia
• Asthenia
• Nervousness
• Dyspepsia
• Abnormal ejaculation
• Sweating
• Anorexia
• Tremor
• Vomiting
• Anorgasmia
• Decreased libido
• Dry mouth
• Rhinitis
• Taste perversion
• Urinary frequency
• Agitation
• Depression
• Dysmenorrhea
• Flatulence
• Hyperkinesia
• Rash

Pregnancy & Lactation

• Consideration of potential risks and benefits when treating pregnant women
• Risk of complications in infants exposed to SSRIs late in pregnancy
• Secretion of fluvoxamine in human breast milk

Precautions & Warnings

• Use with caution in patients with specific medical history
• Impairment of performance of skilled tasks (driving)

Therapeutic Class

• SSRIs & related anti-depressant drugs

Storage Conditions

• Keep below 30°C temperature
• Away from light & moisture
• Keep out of the reach of children

Related Brands